RAPID ALERT

DRAP ALERT NO. Nº I/S/11-22-37

FALSIFIED XANAX 0.5MG TABLETS

Date: 28th November, 2022

Target Audience:

- Regulatory Field Force
- Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
- Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospitals and clinics etc.
- General Public

Problem Statement:

During the market surveillance activities in different areas of Ferozewala District Sheikhupura Punjab, Regulatory Field Force has identified the suspected sample of Xanax 0.5mg Tablets and sent for analysis. The Provincial Drugs Testing Laboratory, has declared the samples as "**spurious"** based on the analysis report. Details of the falsified product is as under: -

Product Name	**Composition**	**Stated manufacturer on label**	**Remarks by DTL**
Xanax 0.5mg Tablet Batch No. **FM7597**	Alprazolam 0.5mg	M/s Pfizer Pakistan Ltd, B-2, S.I.T.E, Karachi.	Spurious "API alprazolam not identified"

Action Initiated: -

The Regulatory Field Force has been directed to increase the market surveillance and **confiscate** this batch of the product. All Pharmacists and chemists working at distributions and Pharmacies should **immediately check** the stock and **stop supplying this batch product**. The remaining stock should be quarantine immediately, and supplier(s) information should be provided to the Regulatory field force (DRAP, Provincial Health Departments and States) in order to ensure the removal of this products.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions / pharmacies / healthcare facilities likely to be affected by this defective batch of product.

DRAP, Islamabad **92 51 9107404** **addl-dir.qa@dra.gov.pk**

Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers / General public: -

Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

All therapeutic goods must be obtained from the licensed pharmacies, and other authorized retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professional in case of any doubt.

DRAP, Islamabad | 92 51 9107404 | addl-dir.qa@dra.gov.pk